IL286929A - Trispecific binding proteins, methods, and uses thereof - Google Patents

Trispecific binding proteins, methods, and uses thereof

Info

Publication number
IL286929A
IL286929A IL286929A IL28692921A IL286929A IL 286929 A IL286929 A IL 286929A IL 286929 A IL286929 A IL 286929A IL 28692921 A IL28692921 A IL 28692921A IL 286929 A IL286929 A IL 286929A
Authority
IL
Israel
Prior art keywords
methods
binding proteins
trispecific binding
trispecific
proteins
Prior art date
Application number
IL286929A
Other languages
Hebrew (he)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of IL286929A publication Critical patent/IL286929A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
IL286929A 2019-04-09 2021-10-03 Trispecific binding proteins, methods, and uses thereof IL286929A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831572P 2019-04-09 2019-04-09
EP19306261 2019-10-02
PCT/US2020/027320 WO2020210392A1 (en) 2019-04-09 2020-04-08 Trispecific binding proteins, methods, and uses thereof

Publications (1)

Publication Number Publication Date
IL286929A true IL286929A (en) 2021-10-31

Family

ID=72751423

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286929A IL286929A (en) 2019-04-09 2021-10-03 Trispecific binding proteins, methods, and uses thereof

Country Status (13)

Country Link
EP (1) EP3953388A1 (en)
JP (1) JP2022527994A (en)
KR (1) KR20210149141A (en)
CN (1) CN113950484A (en)
AU (1) AU2020272839A1 (en)
BR (1) BR112021019915A2 (en)
CA (1) CA3136821A1 (en)
CO (1) CO2021014918A2 (en)
IL (1) IL286929A (en)
MX (1) MX2021012386A (en)
SG (1) SG11202111012QA (en)
TW (1) TW202104261A (en)
WO (1) WO2020210392A1 (en)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200061B2 (en) * 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
JOP20210044A1 (en) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-cd38 antibodies
TWI803876B (en) * 2011-03-28 2023-06-01 法商賽諾菲公司 Dual variable region antibody-like binding proteins having cross-over binding region orientation
CA2996848C (en) * 2014-09-04 2021-01-05 Stemcell Technologies Inc. Soluble antibody complexes for t cell or nk cell activation and expansion
TW202130662A (en) * 2015-01-23 2021-08-16 法商賽諾菲公司 Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
AU2016280159A1 (en) * 2015-06-17 2017-12-07 Genentech, Inc. Anti-HER2 antibodies and methods of use
CN116675776A (en) 2015-10-25 2023-09-01 赛诺菲 Trispecific and/or trivalent binding proteins for the prevention or treatment of HIV infection
CR20180539A (en) 2016-04-13 2019-02-15 Sanofi Sa THREE-SPECIFIC AND / OR TRIVAL UNION PROTEINS
US20230242876A1 (en) * 2016-12-30 2023-08-03 Shanghai Sinobio Biotech Co., Ltd. Bifunctional molecule and use thereof
JP7036909B2 (en) * 2017-10-10 2022-03-15 サノフイ Anti-CD38 antibody and usage
CN113166254A (en) * 2018-10-09 2021-07-23 赛诺菲 Trispecific anti-CD 38, anti-CD 28, and anti-CD 3 binding proteins and methods of use for treating viral infections

Also Published As

Publication number Publication date
CN113950484A (en) 2022-01-18
SG11202111012QA (en) 2021-11-29
AU2020272839A1 (en) 2021-12-02
CO2021014918A2 (en) 2021-11-19
MX2021012386A (en) 2022-01-18
WO2020210392A1 (en) 2020-10-15
TW202104261A (en) 2021-02-01
EP3953388A1 (en) 2022-02-16
BR112021019915A2 (en) 2021-12-07
JP2022527994A (en) 2022-06-07
KR20210149141A (en) 2021-12-08
CA3136821A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
IL277398A (en) Pd-l1 binding affimers, and uses related thereto
PT3443006T (en) Trispecific and/or trivalent binding proteins
EP3452089A4 (en) Bispecific binding proteins and uses thereof
IL278943A (en) Multi-specific binding proteins and improvements thereon
IL265489B (en) Recombinant binding proteins and their use
EP3655432A4 (en) Binding proteins 1
IL268755A (en) Proteins binding her2, nkg2d and cd16
EP3613772A4 (en) Binding molecule specific for lrig-1 protein and use thereof
IL268567A (en) Proteins binding bcma, nkg2d and cd16
EP3689893A4 (en) Immunoglobulin binding protein, and affinity support using same
IL284664A (en) Multispecific binding proteins
EP3515948A4 (en) Coagulation factor binding proteins and uses thereof
EP3380514A4 (en) Cd131 binding proteins and uses thereof
ZA202103259B (en) Modified cas9 protein, and use thereof
EP3705121A4 (en) Emopamil binding protein binding agent and use thereof
EP3689894A4 (en) Immunoglobulin binding protein, and affinity support using same
EP3882266A4 (en) Binding molecule specific to lrig-1 protein, and use thereof
IL284317A (en) Pseudofab-based multispecific binding proteins
IL304317A (en) Tgf-beta-rii binding proteins
EP3700571A4 (en) Alk7 binding proteins and uses thereof
IL289145A (en) Il1rap binding proteins
EP4077385A4 (en) Cxcl10 binding proteins and uses thereof
IL286929A (en) Trispecific binding proteins, methods, and uses thereof
EP3976630A4 (en) Actrii-binding proteins and uses thereof
EP3973550C0 (en) Peptide ionogel composition, methods and uses thereof